Pan-Immune-Inflammatory Value in Patients with Non-Small-Cell Lung Cancer Undergoing Neoadjuvant Immunochemotherapy

References

• Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (Eighth) Edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11(1):39–51. doi:10.1016/j.jtho.2015.09.009
   PubMed Web of Science ®Google Scholar
• Uramoto H, Tanaka F. Recurrence after surgery in patients with NSCLC. Transl Lung Cancer Res. 2014;3(4):242–249. doi:10.3978/j.issn.2218-6751.2013.12.05
   PubMedGoogle Scholar
• Taylor MD, Nagji AS, Bhamidipati CM, et al. Tumor recurrence after complete resection for non-small cell lung cancer. Ann Thorac Surg. 2012;93(6):1813–1820. doi:10.1016/j.athoracsur.2012.03.031
   PubMed Web of Science ®Google Scholar
• Forde PM, Spicer J, Lu S, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386:1973–1985. doi:10.1056/NEJMoa2202170
   PubMed Web of Science ®Google Scholar
• Melek H, Çetinkaya G, Özer E, et al. Pathological complete response after neoadjuvant/induction treatment: where is its place in the lung cancer staging system? Eur J Cardiothorac Surg. 2019;56(3):604–611. doi:10.1093/ejcts/ezz044
   PubMed Web of Science ®Google Scholar
• Martinez-Meehan D, Lutfi W, Dhupar R, et al. Factors associated with survival in complete pathologic response non-small cell lung cancer. Clin Lung Cancer. 2020;21(4):349–356. doi:10.1016/j.cllc.2020.03.003
   PubMed Web of Science ®Google Scholar
• Shu CA, Gainor JF, Awad MM, et al. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, Phase 2 trial. Lancet Oncol. 2020;21(6):786–795. doi:10.1016/S1470-2045(20)30140-6
   PubMed Web of Science ®Google Scholar
• Rothschild SI, Zippelius A, Eboulet EI, et al. SAKK 16/14: durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small-cell lung cancer-A multicenter single-arm phase II trial. J Clin Oncol. 2021;39(26):2872–2880. doi:10.1200/JCO.21.00276
   PubMed Web of Science ®Google Scholar
• Provencio M, Nadal E, Insa A, et al. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020;21(11):1413–1422. doi:10.1016/S1470-2045(20)30453-8
   PubMed Web of Science ®Google Scholar
• Chen Y, Wen S, Xia J, et al. Association of dynamic changes in peripheral blood indexes with response to PD-1 inhibitor-based combination therapy and survival among patients with advanced non-small cell lung cancer. Front Immunol. 2021;2021:12.
   Google Scholar
• Insa A, Martín-Martorell P, Di Liello R, et al. Which treatment after first line therapy in NSCLC patients without genetic alterations in the era of immunotherapy? Crit Rev Oncol Hematol. 2022;169:103538. doi:10.1016/j.critrevonc.2021.103538
   PubMed Web of Science ®Google Scholar
• Bagley SJ, Kothari S, Aggarwal C, et al. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. Lung Cancer. 2017;106:1–7. doi:10.1016/j.lungcan.2017.01.013
   PubMed Web of Science ®Google Scholar
• Russo A, Russano M, Franchina T, et al. Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): a large retrospective multicenter study. Adv Ther. 2020;37(3):1145–1155. doi:10.1007/s12325-020-01229-w
   PubMed Web of Science ®Google Scholar
• Cannon NA, Meyer J, Iyengar P, et al. Neutrophil-lymphocyte and platelet-lymphocyte ratios as prognostic factors after stereotactic radiation therapy for early-stage non-small-cell lung cancer. J Thorac Oncol. 2015;10(2):280–285. doi:10.1097/JTO.0000000000000399
   PubMed Web of Science ®Google Scholar
• Peng L, Wang Y, Liu F, et al. Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors. Cancer Immunol Immunother. 2020;69(9):1813–1822. doi:10.1007/s00262-020-02585-w
   PubMed Web of Science ®Google Scholar
• Sekine K, Kanda S, Goto Y, et al. Change in the lymphocyte-to-monocyte ratio is an early surrogate marker of the efficacy of nivolumab monotherapy in advanced non-small-cell lung cancer. Lung Cancer. 2018;124:179–188. doi:10.1016/j.lungcan.2018.08.012
   PubMed Web of Science ®Google Scholar
• Sun X, Feng Y, Zhang B, et al. The role of neutrophil-to-lymphocyte ratio in predicting pathological response for resectable NSCLC treated with neoadjuvant chemotherapy combined with PD-1 checkpoint inhibitors. Cancer Res Treat. 2021;54:1017–1029. doi:10.4143/crt.2021.1007
   PubMed Web of Science ®Google Scholar
• Fucà G, Guarini V, Antoniotti C, et al. The pan-immune-inflammation value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials. Br J Cancer. 2020;123(3):403–409. doi:10.1038/s41416-020-0894-7
   PubMed Web of Science ®Google Scholar
• Ligorio F, Fucà G, Zattarin E, et al. The pan-immune-inflammation-value predicts the survival of patients with human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer treated with first-line taxane-trastuzumab-pertuzumab. Cancers. 2021;13(8). doi:10.3390/cancers13081964
   Web of Science ®Google Scholar
• Diem S, Schmid S, Krapf M, et al. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer. 2017;111:176–181. doi:10.1016/j.lungcan.2017.07.024
   PubMed Web of Science ®Google Scholar
• Zheng L, Xiong A, Wang S, et al. Decreased monocyte-to-lymphocyte ratio was associated with satisfied outcomes of first-line PD-1 inhibitors plus chemotherapy in stage IIIB-IV non-small cell lung cancer. Front Immunol. 2023;14:1094378. doi:10.3389/fimmu.2023.1094378
   PubMed Web of Science ®Google Scholar
• Guo M, Sun T, Zhao Z, Ming L. Preoperative platelet to albumin ratio predicts outcome of patients with non-small-cell lung cancer. Ann Thorac Cardiovasc Surg. 2021;27(2):84–90. doi:10.5761/atcs.oa.20-00090
   PubMed Web of Science ®Google Scholar
• Tong YS, Tan J, Zhou XL, Song YQ, Song YJ. Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer. J Transl Med. 2017;15(1):221. doi:10.1186/s12967-017-1326-1
   PubMed Web of Science ®Google Scholar
• Johannet P, Sawyers A, Qian Y, et al. Baseline prognostic nutritional index and changes in pretreatment body mass index associate with immunotherapy response in patients with advanced cancer. J Immunother Cancer. 2020;8(2):e001674. doi:10.1136/jitc-2020-001674
   PubMed Web of Science ®Google Scholar
• Qi Q, Zhuang L, Shen Y, et al. A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy. Cancer. 2016;122(14):2158–2167. doi:10.1002/cncr.30057
   PubMed Web of Science ®Google Scholar
• Hua X, Duan F, Zhai W, et al. A novel inflammatory-nutritional prognostic scoring system for patients with early-stage breast cancer. J Inflamm Res. 2022;15:381–394. doi:10.2147/JIR.S338421
   PubMed Web of Science ®Google Scholar
• Travis WD, Dacic S, Wistuba I, et al. IASLC multidisciplinary recommendations for pathologic assessment of lung cancer resection specimens after neoadjuvant therapy. J Thorac Oncol. 2020;15(5):709–740. doi:10.1016/j.jtho.2020.01.005
   PubMed Web of Science ®Google Scholar
• Forde PM, Chaft JE, Smith KN, et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med. 2018;378(21):1976–1986. doi:10.1056/NEJMoa1716078
   PubMed Web of Science ®Google Scholar
• Song JM, Qian X, Teferi F, Pan J, Wang Y, Kassie F. Dietary diindolylmethane suppresses inflammation-driven lung squamous cell carcinoma in mice. Cancer Prev Res. 2015;8(1):77–85. doi:10.1158/1940-6207.CAPR-14-0245
   PubMed Web of Science ®Google Scholar
• Ben-Baruch A. Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Semin Cancer Biol. 2006;16(1):38–52. doi:10.1016/j.semcancer.2005.07.006
   PubMed Web of Science ®Google Scholar
• Zhai WY, Duan FF, Chen S, et al. A novel inflammatory-related gene signature based model for risk stratification and prognosis prediction in lung adenocarcinoma. Front Genet. 2021;12:798131. doi:10.3389/fgene.2021.798131
   PubMed Web of Science ®Google Scholar
• Zhang Q, Song MM, Zhang X, et al. Association of systemic inflammation with survival in patients with cancer cachexia: results from a multicentre cohort study. J Cachexia Sarcopenia Muscle. 2021;12(6):1466–1476. doi:10.1002/jcsm.12761
   PubMed Web of Science ®Google Scholar
• Simonaggio A, Elaidi R, Fournier L, et al. Variation in neutrophil to lymphocyte ratio (NLR) as predictor of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (mNSCLC) patients treated with nivolumab. Cancer Immunol Immunother. 2020;69(12):2513–2522. doi:10.1007/s00262-020-02637-1
   PubMed Web of Science ®Google Scholar
• Gambichler T, Said S, Abu Rached N, et al. Pan-immune-inflammation value independently predicts disease recurrence in patients with Merkel cell carcinoma. J Cancer Res Clin Oncol. 2022;148:3183–3189. doi:10.1007/s00432-022-03929-y
   PubMed Web of Science ®Google Scholar
• Corti F, Lonardi S, Intini R, et al. The pan-immune-inflammation value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors. Eur J Cancer. 2021;150:155–167. doi:10.1016/j.ejca.2021.03.043
   PubMed Web of Science ®Google Scholar
• Zhao ZR, Yang CP, Chen S, et al. Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer. Oncoimmunology. 2021;10(1):1996000. doi:10.1080/2162402X.2021.1996000
   PubMed Web of Science ®Google Scholar
• Tuminello S, Alpert N, Veluswamy R, et al. Modulation of chemoimmunotherapy efficacy in non-small cell lung cancer by sex and histology: a real-world, patient-level analysis. BMC Cancer. 2022;22(1):80. doi:10.1186/s12885-022-09187-y
   PubMed Web of Science ®Google Scholar